Belantamab mafodotin provides a community-friendly BCMA-directed therapy option for relapsed/refractory myeloma, says Hearn Jay Cho, MD, PhD.
Hearn Jay Cho, MD, PhD
Advertisement
Hearn Jay Cho, MD, PhD, is chief medical officer at the Multiple Myeloma Research Foundation.
Articles by Hearn Jay Cho, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5
